Apr 30 |
Exelixis down 7% as Q1 financial results disappoint
|
Apr 30 |
Exelixis (EXEL) Reports Q1 Earnings: What Key Metrics Have to Say
|
Apr 30 |
Exelixis Inc (EXEL) Q1 2024 Earnings: Mixed Results Amidst Restructuring Efforts
|
Apr 30 |
Exelixis Non-GAAP EPS of $0.17 misses by $0.12, revenue of $425.2M misses by $35.27M
|
Apr 30 |
Exelixis Announces First Quarter 2024 Financial Results and Provides Corporate Update
|
Apr 29 |
Exelixis Q1 2024 Earnings Preview
|
Apr 27 |
The Top 3 Biotech Stocks to Buy in April 2024
|
Apr 26 |
Analysts Estimate Immunome, Inc. (IMNM) to Report a Decline in Earnings: What to Look Out for
|
Apr 26 |
Merus (MRUS) Moves 7.1% Higher: Will This Strength Last?
|
Apr 17 |
Institutional investors in Exelixis, Inc. (NASDAQ:EXEL) lost 3.8% last week but have reaped the benefits of longer-term growth
|